AN2 Therapeutics Completes First-in-Human Trial, Setting Up the Next Catalyst for ANTX

AN2 Therapeutics, Inc. (ANTX) announced an update on their ongoing clinical study.

The Phase 1 trial “A Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998” tests AN2 Therapeutics, Inc.’s new oral drug in healthy volunteers. It aims to understand basic safety, how well it is tolerated, and how the body processes it, which is a key early step for any future patient studies.

The study tests AN2-502998, an oral capsule, against a matching placebo. The goal is to see how safe different single and multiple dose levels are and how the drug moves through the body over time, creating a base for future dose choices in patient trials.

This is an interventional Phase 1 study with healthy adults who are randomly assigned to study drug or placebo. It uses a double-blind design so neither the volunteers nor the investigators know who gets AN2-502998, and the main purpose is basic scientific insight, not direct treatment, reducing bias and improving data quality.

The trial began after initial submission on May 31, 2025, marking the formal start of human testing for AN2-502998. The study is now listed as completed, and the most recent update was submitted on April 28, 2026, signaling that data collection is done even though full results are not yet posted.

For investors, completion of this first-in-human study is a de-risking step for ANTX, since it clears an early safety hurdle needed before pursuing larger trials that can move the stock. Market reaction will depend on detailed safety and exposure data, and investors will compare AN2-502998’s profile to other early-stage anti-infective and rare disease programs in the sector.

News that the study is completed and recently updated may support cautious optimism in ANTX shares, though the lack of posted results can limit any immediate re-rating until data are public. The trial status confirms the program is progressing on schedule and investors can track new disclosures as they appear on the ClinicalTrials portal, where the ongoing record remains updated.

To learn more about ANTX’s potential, visit the AN2 Therapeutics, Inc. drug pipeline page.